Werewolf Therapeutics
About Werewolf Therapeutics
Werewolf Therapeutics, Inc. is an oncology biotherapeutics company unleashing the power of proinflammatory immune modulators to develop next-generation, transformative cancer therapeutics. The company is advancing a pipeline of treatments designed to focus the body’s immune response to selectively target cancer.
Under precise conditions, Werewolf’s technology allows it to zero in on tumors using validated mechanisms that are known cancer killers, while preventing unwanted side effects on non-target tissues – ultimately delivering a more clinically meaningful impact for patients.
Werewolf’s proprietary PREDATOR™ protein engineering platform combines a variety of approaches to actively silence the drug while in systemic circulation, optimize its pharmacokinetic profile, and rapidly and efficiently transform into the fully active state upon reaching the tumor microenvironment for maximum therapeutic potential.
Werewolf is creating a new era of tumor-selective, systemically delivered drugs with the potential to deliver more effective, less toxic treatments for people with cancer, with the goal of vastly improving their lives.
44 articles about Werewolf Therapeutics
-
Werewolf Therapeutics to Participate in May Investor Conferences
5/1/2023
Werewolf Therapeutics, Inc. today announced that management will participate at the following conferences in the month of May.
-
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
4/19/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology ResearchOnline First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 (IL-12) INDUKINETM molecule.
-
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/23/2023
Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.
-
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
3/16/2023
Werewolf Therapeutics, Inc. today announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19.
-
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
3/15/2023
Werewolf Therapeutics, Inc. today announced the publication of an abstract summarizing an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.
-
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
2/24/2023
Werewolf Therapeutics today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating WTX-330.
-
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
2/7/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will present virtually at 8:40AM ET on February 16th at the SVB Securities Global Biopharma Conference, taking place February 14th -16th , 2023.
-
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
11/10/2022
Werewolf Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2022.
-
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
11/10/2022
Werewolf Therapeutics, Inc. today announced that it will present preclinical data on mWTX-330, a mouse surrogate of its interleukin-12 (“IL-12”) INDUKINETM product candidate, WTX-330, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) being held November 8-12, 2022, in Boston, and virtually.
-
Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences
11/7/2022
Werewolf Therapeutics, Inc. announced upcoming oncology research and investor community events in which Werewolf scientists and management will participate.
-
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
8/11/2022
Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2022.
-
Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
6/6/2022
Werewolf Therapeutics, Inc. announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 9:00AM ET on June 9 during the Jefferies Global Healthcare Conference taking place June 8-10, 2022 in New York, NY.
-
Werewolf Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
5/10/2022
Werewolf Therapeutics, Inc. provided a business update and reported financial results for the quarter ended March 31, 2022.
-
The deal marks the first immuno-oncology program for Jazz Pharma. With it, they are trying to become a leading oncology company. Here's more about their success. -
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule
4/7/2022
Jazz Pharmaceuticals plc and Werewolf Therapeutics, Inc. today announced that the companies have entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613.
-
Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Highlights
3/24/2022
Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment
3/16/2022
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research of preclinical data for its lead molecule WTX-124, a systemically delivered Interleukin-2 (IL-2) INDUKINE™ molecule.
-
Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
3/15/2022
Werewolf Therapeutics, Inc. announced the publication of two abstracts summarizing upcoming poster presentations at the American Association for Cancer Research Annual Meeting.
-
Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference
2/8/2022
Werewolf Therapeutics, Inc. announced that management will present at the SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022.
-
Werewolf Therapeutics is designing and developing molecules that unleash the natural ferocity of cytokines for the treatment of cancer.